Document is current
Any future updates will be listed below
-
Authors
Baldwin, Eric T.
van Eeuwen, Trevor https://orcid.org/0000-0003-0549-1702
Hoyos, David
Zalevsky, Arthur https://orcid.org/0000-0001-6987-8119
Tchesnokov, Egor P.
Sánchez, Roberto
Miller, Bryant D. https://orcid.org/0009-0006-9145-8499
Di Stefano, Luciano H.
Ruiz, Francesc Xavier https://orcid.org/0000-0002-0457-0030
Hancock, Matthew
Işik, Esin
Mendez-Dorantes, Carlos https://orcid.org/0000-0002-8190-8568
Walpole, Thomas
Nichols, Charles
Wan, Paul
Riento, Kirsi
Halls-Kass, Rowan
Augustin, Martin
Lammens, Alfred
Jestel, Anja
Upla, Paula
Xibinaku, Kera
Congreve, Samantha https://orcid.org/0009-0001-5277-2235
Hennink, Maximiliaan https://orcid.org/0009-0000-1589-1780
Rogala, Kacper B. https://orcid.org/0000-0001-5997-7770
Schneider, Anna M.
Fairman, Jennifer E. https://orcid.org/0000-0002-2319-1773
Christensen, Shawn M.
Desrosiers, Brian
Bisacchi, Gregory S.
Saunders, Oliver L.
Hafeez, Nafeeza
Miao, Wenyan
Kapeller, Rosana
Zaller, Dennis M.
Sali, Andrej https://orcid.org/0000-0003-0435-6197
Weichenrieder, Oliver https://orcid.org/0000-0001-5818-6248
Burns, Kathleen H. https://orcid.org/0000-0003-1620-3761
Götte, Matthias https://orcid.org/0000-0001-6213-5806
Rout, Michael P. https://orcid.org/0000-0003-2010-706X
Arnold, Eddy https://orcid.org/0000-0003-2612-9622
Greenbaum, Benjamin D. https://orcid.org/0000-0001-6153-8793
Romero, Donna L. https://orcid.org/0000-0002-3009-1965
LaCava, John https://orcid.org/0000-0002-6307-7713
Taylor, Martin S. https://orcid.org/0000-0003-1560-9276
- License Information
-
More Information
Article History
Received: 26 May 2023
Accepted: 7 December 2023
First Online: 14 December 2023
Competing interests
: M.S.T., B.D.G., M.G., K.H.B. and E.A. hold equity in and have received consulting fees from ROME Therapeutics. J.L. holds equity in ROME Therapeutics. D.H. and E.T. have received consulting fees from ROME Therapeutics. Research conducted at Proteros Biostructures and Charles River Laboratory was contracted by ROME Therapeutics. Research for this project in the Götte laboratory was sponsored by ROME Therapeutics. M.S.T. has received consulting fees from Tessera Therapeutics. K.H.B. declares relationships with Alamar Biosciences, Genscript, Oncolinea/PrimeFour Therapeutics, Scaffold Therapeutics, Tessera Therapeutics and Transposon Therapeutics.
